Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DB2U3O
|
|||
| Drug Name |
GSK3640254
|
|||
| Synonyms |
GSK'254
Click to Show/Hide
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62] | Phase 2 | [1] | |
| Company |
ViiV Healthcare
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Maturation (HIV Mat) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03784079) A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults. U.S. National Institutes of Health. | |||
| REF 2 | Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next-generation HIV-1 maturation inhibitor. Pharmacol Res Perspect. 2020 Dec;8(6):e00671. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.